George Abraham, MD
Family Medicine · Vicksburg, MSNPI 1184669798
Payments from drug & device makers
Across 124 payments — averaging $71.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals AS$7K
- Novo Nordisk$487
- GSK$250
- AbbVie$235
- Abbott$163
- Alpha Cognition USA, Inc.$125
- plus $596 from 15 others
What the payments were for
- Food & beverage$1,856100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals AS | 7 | $7,040 |
| Novo Nordisk | 38 | $487 |
| GSK | 17 | $250 |
| AbbVie | 14 | $235 |
| Abbott | 8 | $163 |
| Alpha Cognition USA, Inc. | 2 | $125 |
| Astellas Pharma US Inc | 6 | $95 |
| Amarin Pharma, Inc. | 7 | $90 |
| AstraZeneca | 4 | $57 |
| Boehringer Ingelheim | 3 | $56 |
| Mylan Specialty L.p. | 3 | $48 |
| Sunovion Pharmaceuticals Inc. | 2 | $44 |
| Lilly USA, LLC | 3 | $42 |
| Pfizer | 3 | $38 |
| Insmed, Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $24 |
| Dexcom, Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| United Therapeutics Corporation | 1 | $15 |
| Novartis | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
How this compares
$8,896 in reported general payments places this provider in the 90th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 87 | $62,345 |
| JardianceEmpagliflozin | 52 | $55,781 |
| OzempicSemaglutide | 44 | $54,790 |
| XifaxanRifaximin | 12 | $36,858 |
| LinzessLinaclotide | 51 | $28,307 |
| EntrestoSacubitril/Valsartan | 17 | $27,590 |
| TrulicityDulaglutide | 26 | $25,051 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $24,948 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $18,713 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $7,529 |
| MyrbetriqMirabegron | 13 | $5,804 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,659 |
| MovantikNaloxegol Oxalate | 12 | $4,798 |
| Gabapentin | 339 | $4,255 |
| ZenpepLipase/Protease/Amylase | 11 | $3,949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $38 | $62,34587 claims |
| Boehringer IngelheimJardiance | $56 | $55,78152 claims |
| Novo NordiskOzempic | $487 | $54,79044 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $11 | $36,85812 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $250 | $30,60843 claims |
| AbbVieLinzess | $235 | $28,30751 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $42 | $28,20755 claims |
| NovartisEntresto | $15 | $27,59017 claims |
| AstraZenecaSymbicort | $57 | $7,52920 claims |
| Astellas Pharma US IncMyrbetriq | $95 | $5,80413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Vicksburg
- Robert GiffinVicksburg$117K
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.